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Gene Dosage Analysis Identifies Large Deletions
of the FECH Gene in 10% of Families with
Erythropoietic Protoporphyria
Sharon D. Whatley1, Nicola G. Mason1, S. Alexander Holme2, Alex V. Anstey3, George H. Elder1 and
Michael N. Badminton1
Erythropoietic protoporphyria (EPP) is an inherited cutaneous porphyria characterized by partial deficiency of
ferrochelatase (FECH), accumulation of protoporphyrin IX in erythrocytes, skin, and liver, and acute
photosensitivity. Genetic counseling in EPP requires identification of FECH mutations, but current sequen-
cing-based procedures fail to detect mutations in about one in six families. We have used gene dosage analysis
by quantitative PCR to identify large deletions of the FECH gene in 19 (58%) of 33 unrelated UK patients with
EPP in whom mutations could not be detected by sequencing. Seven deletions were identified, six of which
were previously unreported. Breakpoints were identified for six deletions (c.1–7887–IVS1þ 2425insTTCA;
c.1–9629–IVS1þ 2437; IVS21987–IVS4þ 352del; c.768–IVS7þ 244del; IVS7þ 2784–IVS9þ 108del; IVS6þ 2350–
TGAþ 95del). Five breakpoints were in intronic repeat sequences (AluSc, AluSq, AluSx, L1MC4). The remaining
deletion (Del Ex3–4) is likely to be a large insertion–deletion. Combining quantitative PCR with routine
sequencing increased the sensitivity of mutation detection in 189 unrelated UK patients with EPP from 83% (95%
CI: 76–87%) to 93% (CI: 88–96%) (P¼ 0.003). Our findings show that large deletions of the FECH gene are an
important cause of EPP. Gene dosage analysis should be incorporated into routine procedures for mutation
detection in EPP.
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INTRODUCTION
Erythropoietic protoporphyria (EPP) (OMIM 177,000) is an
inherited cutaneous porphyria caused by partial deficiency
of ferrochelatase (FECH) (EC 4.99.1.1), the final enzyme
in the heme biosynthetic pathway, which catalyzes the
insertion of ferrous iron into protoporphyrin IX to form heme.
Deficiency of FECH leads to accumulation of protoporphyrin
IX in erythrocytes, plasma, skin, and liver. Accumulation
of protoporphyrin in the skin produces lifelong acute
photosensitivity while its deposition in the liver leads
to hepatobiliary disease in some patients (Todd, 1994;
Meerman, 2000).
The inheritance of EPP is complex. In most families,
clinical expression requires inheritance of a hypomorphic
FECH IVS3-48C trans to a disabling FECH mutation that is
inherited in an autosomal dominant fashion (Gouya et al.,
2006) but rare families with autosomal recessive EPP have
been reported (Lamoril et al., 1991; Sarkany et al., 1994; Poh-
Fitzpatrick et al., 2002; Whatley et al., 2004; Gouya et al.,
2006). The frequency of the hypomorphic FECH allele varies
between populations (Gouya et al., 2006), being present in
about 12% of white Europeans (Gouya et al., 2002, 2006;
Whatley et al., 2004) but in 68% of Japanese (Saruwatari
et al., 2006). Molecular analysis to identify the IVS3-48C
allele and disease-specific mutations in the FECH gene is
important for accurate genetic counseling of families with
EPP (Gouya et al., 2002).
Over 120 mutations in the FECH gene, which contains
11 exons spread over 45 kb, have been reported in EPP, most
of which are restricted to one or a few families (Gouya et al.,
2006; Saruwatari et al., 2006; Aurizi et al., 2007). Apart from
one complete gene deletion (Magness et al., 1994) and a
partial deletion (Wood et al., 2006), all have been detected
using methods that depend only on sequencing of exons and
their flanking regions, including up to 1.3 kb of 50 non-coding
sequence, to identify mutations. This approach fails to
identify an FECH mutation in about one in six families
(Ru¨fenacht et al., 1998; Whatley et al., 2004; Gouya et al.,
2006). Here we show that gene dosage analysis by
quantitative PCR detects gross deletions of one or more
FECH exons in 19 of 33 (58%) of such ‘‘mutation-negative’’
families and that deletions of this type are present in 10% of
UK families with EPP.
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RESULTS
Direct sequencing of all exons, 30–250 bp of intronic flanking
regions, and 1,000 kb of 50 untranslated region (UTR)
identified an FECH mutation on one or both alleles in 156
(83%) of our 189 unrelated patients, 149 of whom had a
mutation on only one allele. Genotyping of the 33 mutation-
negative patients showed that 28 (85%) patients carried an
FECH IVS3-48C allele, a significantly lower frequency than in
the 149 patients who were heterozygous for an FECH
mutation, all but one of whom had at least one IVS3-48C
allele (w2 13.3; Po0.005).
Gene dosage analysis by quantitative PCR of genomic
DNA from the 33 mutation-negative patients identified
deletions encompassing one or more exons in 19 (58%)
patients, 18 of whom were either FECH IVS3-48C/T hetero-
zygotes or had the IVS3-48C allele trans to a deletion
(Table 1). Seven different deletions were detected, one of
which has been described previously (Wood et al., 2006)
(Table 1). Exon 1 was deleted in five patients; genotyping
with three highly informative microsatellite markers, two
flanking the FECH gene and one in intron 4, identified two
haplotypes that differed only at the 50 flanking site. Two
different deletions were identified: three patients had a
10,379 bp deletion with a small 4 bp insertion and two
patients had a 12,133 bp deletion (Table 1). Two patients had
lost exons 3 and 4; one has previously been described (Wood
et al., 2006), the other had a deletion for which breakpoints
were not identified (Table 1). In two patients, a small deletion
involving part of exon 7 and 244 bp of 30 flanking sequence
removed the region in which one of the primers for
amplification of this exon is usually based. The presence of
a stop codon 68 codons 30 to this deletion suggests that any
mRNA produced from this allele will be truncated and
unstable. Exons 8 and 9 were deleted in eight patients;
genotyping with three microsatellite markers showed that this
mutation was present in at least two different FECH
haplotypes. The largest deletion removed exons 7, 8, 9, 10,
and 11 and was present in two patients.
Breakpoints for six deletions were defined by sequencing
(Table 2). The 10.4 kb exon 1 deletion contained a four-base
insert with a sequence that was repeated in the 50 flanking
region (Table 2) and 30 bp 30 to the insertion. For four of the
five other deletions, the breakpoints shared the same 3, 4, or
5 bp sequences at the deletion junctions (Table 2). The 30
breakpoints of both exon 1 deletion and the exon 7 deletion
and the 50 breakpoint of the exon 8–9 deletion were all sited
in Alu repeat regions while the 50 breakpoint of the exon 7–11
deletion was in an L1MC4 repeat sequence (Table 2). These
features have been reported for large deletions in other genes
and are believed to facilitate homologous recombination
(Woods-Samuels et al., 1991; Laccone et al., 2004).
We were unable to identify the breakpoint for one
deletion. This patient was heterozygous for a deletion that
included exons 3 and 4 and surrounding sequence from IVS2-
88 to IVS4þ2046 and thus differed from the exon 3–4
deletion with defined breakpoints recently described in two
Italian families (Di Pierro et al., 2007). PCR amplification
using primers flanking the deleted region gave a 7 kb band
consistent with the size of the deletion as identified by gene
dosage analysis. No smaller product was identified using
amplification conditions that are capable of detecting
fragments as small as 100 bp. Restriction enzyme (NdeI)
digestion of the 7 kb amplicon gave a normal pattern
consistent with the amplicon coming from the normal allele
alone. These findings exclude the presence of a 7 kb
insertion–deletion but not of an insertion–deletion too large
to amplify.
DISCUSSION
Most patients with EPP are heterozygous for disabling
mutations in the FECH gene (Gouya et al., 2006). Intragenic
deletions involving entire exons and their flanking regions,
including primer binding sites, are not identified in hetero-
zygotes by methods for mutation detection that rely on direct
sequencing of amplified genomic DNA because sequencing
does not distinguish between amplification of one or both
alleles. Quantitative analysis of amplified genomic DNA is
required for this purpose. Here, we have used gene dosage
analysis to show that large deletions of the FECH gene, likely
to abolish all FECH activity, were present in 19 (58%) of 33
patients with EPP in whom FECH mutations were not
identified by sequencing.
Such deletions are an important cause of human disease
and represent 5.6% of all mutations in the human gene
mutation database (www.hgmd.cf.ac.uk). There is evidence
that they result from various molecular interactions that are
Table 1. Deletions in the FECH gene in patients with EPP
Number of patients Deleted exons Deletion Size of deletion (bp) FECH IVS3-48 genotypes
3 Exon 1 c.1–7887 to IVS1+2425insTTCA 10,379 C/T
2 Exon 1 c.1–9629 to IVS1+2437 12,133 C/T
11 Exons 3, 4 IVS2-1987 to IVS4+352 4,425 C/
1 Exons 3, 4 See text 47,000 C/
2 Exon 7 (partial) c.768 to IVS7+244 280 C/T, T/T
8 Exons 8, 9 IVS7+2784 to IVS9+108 2,196 C/T
2 Exons 7–11 IVS6+2350 to TGA+95 9,889 C/T
1Wood et al. (2006).
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dependent on the features of the surrounding DNA sequence
(Abeysinghe et al., 2006). Repetitive elements, which were
present in all but one of the deletions for which we defined
breakpoints, are known to facilitate the formation of
secondary structures such as hairpin loops and cruciforms
(non-B DNA conformations) that have been shown to
coincide with the breakpoints of gross deletions (Chuzhanova
et al., 2003; Bacolla et al., 2004).
The 33 patients came from a cohort of 189 apparently
unrelated patients identified by a cross-sectional study of EPP
in the UK (Holme et al., 2006). FECH mutations were
identified by sequencing in 156 (83%) of these 189 patients.
Here we show that a further 19 (10%) patients had large
intragenic deletions. Thus sequencing combined with gene
dosage analysis identifies mutations in 175 of UK patients
with EPP, increasing the sensitivity of mutation detection to
93% (95% confidence interval: 88–96%) (w2 8.7; P¼0.003),
which is higher than those reported previously (Ru¨fenacht
et al., 1998; Whatley et al., 2004; Gouya et al., 2006).
Only one of the 19 patients with deletions was not hetero-
zygous for the hypomorphic FECH IVS3-48C allele (Table 1).
This patient had the smallest deletion that we identified as
involving exon 7 and its 30 flanking region (Tables 1 and 2).
However, it is unlikely that the mutant allele gives rise to a
stable truncated protein (see Results) capable of exerting a
dominant-negative effect on FECH activity, as reported for an
exon 10 deletion in the mouse (Magness et al., 2002). At
present, it is not clear why rare patients with the dominant form
of EPP who have a mutation trans to a normal FECH IVS3-48T
allele develop photosensitivity (Wiman et al., 2003).
Sequencing combined with gene dosage analysis failed to
identify an FECH mutation in 14 (7%) of UK patients with
EPP. Ten of these patients were heterozygous for the
hypomorphic FECH IVS3-48C allele, a proportion that is
significantly higher than in the UK population (w2 26.0,
Po0.001). This suggests that most, if not all, of these 10
patients may be heterozygous for deleterious FECH mutations
that lie in regions of the gene that determine expression but
are outside the regions that we sequenced. The other four
patients all had the genotype FECH IVS3-48T/T, a proportion
that is much higher than that in other groups of EPP patients
(Risheq et al., 2003; Gouya et al., 2006) except for those
with mutations on both FECH alleles (Whatley et al., 2004;
Gouya et al., 2006). It seems unlikely that these patients are
homozygous or compound heterozygotes for FECH mutations
that were not detected by our methods since all patients with
recessive EPP yet reported have had at least one intra-exonic
mutation (Whatley et al., 2004; Gouya et al., 2006).
Alternatively, at least some of these patients may have
mutations in genes other than FECH. Deletion of the
Irp2 gene has recently been shown to produce proto-
porphyria in mice (Cooperman et al., 2006), and the
possibility that EPP may also be caused by mutation of genes
that regulate the supply of substrates to FECH remains to be
excluded.
MATERIALS AND METHODS
Patients
Blood samples were obtained from 189 apparently unrelated
patients with EPP as part of a cross-sectional study of EPP in the
Table 2. Deletion breakpoints in the FECH gene
Deleted exon(s) Sequence Breakpoints Repeat sequence
1 (10.4 kb) Junctional gttcacgcacaTTCAggctcactgca
50WT gtgcattcaggttcacgcaca —
30WT ggctcactgcaacctccgcct AluSc
1 (12.1 kb) Junctional tttgctgttgtTGCCCggcctgtttgt
50WT tacacagagttttgctgttgtTGCCC —
30WT TGCCCggcctgtttgtaggccttcta AluSq
3, 41 Junctional 50 ctttagttttcGAGgctgctgctat 30
50WT atcatagtatctttagttttcGAG —
30WT GAGgctgctgctattattgccttt —
7 Junctional 50agagaagcgagGTGtcacccaggct 30
50WT ccacttgagaagagaagcgagGTG —
30 WT GTGtcacccaggctggagtgcaat AluSx
8, 9 Junctional 50 ctatttttctcTTTGcatgtacggt 30
50WT ctaaaattactatttttctcTTTG AluSx
30WT TTTGcatgtacggtgtcctcattc —
7, 8, 9, 10, 11 Junctional 50 tgggaccacag||catccttcctt 30
50WT tgctgagtagctgggaccaca L1MC4
30 WT catccttccttgatatatata —
Wild-type (WT) sequences 50 and 30 to the breakpoints are shown. Junction points, except for the flush junction indicated by ||, and homologous sequences
present at both the 50 and 30 breakpoints are in capitals. The inserted sequence is indicated by italic capitals.
1Previously reported (Wood et al., 2006).
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UK (Holme et al., 2006). We investigated 33 of these patients (32
white British, one of Iraqi descent) in whom an FECH mutation could
not be identified by direct sequencing of all exons, 30–250 bp of
intronic flanking regions, and 1,000 kb of 50 UTR. Total erythrocyte
porphyrin was increased in all 33 patients (mean 25.6 mmol/l, range
6.2–65.7mmol/l; reference range 0.4–1.7 mmol/l) and was mainly free
protoporphyrin.
The study was conducted in accordance with the Declaration of
Helsinki Principles for medical research involving human subjects
and its subsequent amendments. Prior approval was obtained from
the North West Multicentre Research Ethics Committee and 84 local
research ethics committees. All patients or their parents gave
informed consent.
Preparation of DNA
Genomic DNA was extracted from whole blood using the QIAamp
DNA purification kit (Qiagen, Crawley, UK) for sequencing and the
Flexigene kit (Qiagen) for dosage studies.
Gene dosage analysis
A multiplex PCR was designed to simultaneously amplify exons 2–9
and 11 of the FECH gene, along with exon 9 of the HMBS gene and
exon 5 of the PPOX gene as internal controls. Exons 1 and 10 did not
amplify consistently within the multiplex, so they were analyzed
separately with exon 1 of the UROS gene and exon 4 of the HMBS
gene as internal controls. A fluorescent (50 FAM) label was
incorporated into one of each primer pair. Details of the primers
used for gene dosage analysis are available from the authors.
Amplification was carried out in 20 ml volumes containing 5.39 ml
DNA, 3.45 ml primer mix (0.5–1.5 pmol (final concentration) of each
primer), and 10 ml 2 Qiagen multiplex PCR master mix (containing
HotStarTaq DNA polymerase, Qiagen multiplex PCR buffer (6 mM
MgCl2, pH 8.7), dNTP mix). An initial denaturation of 15 minutes at
951C was followed by 20 cycles of denaturation for 30 seconds at
941C, annealing for 1 minute 30 seconds at 641C, and extension for
1 minute 30 seconds at 721C, with a final extension for 10 minutes at
721C. The PCR products (2 ml) were added to a mixture containing
formamide (10 ml) and GS500 standard (0.3 ml) (PE Applied
Biosystems, Cheshire, UK) and denatured at 951C for 3 minutes.
The samples were run on an ABI Prism 310 analyser at 601C using
POP4 polymer (PE Applied Biosystems).
To determine the gene dosage for each exon, the peak areas were
compared with each other and against controls (Yau et al., 1996). A
locus with a double copy will give a theoretical value of 1.0 whereas
a locus with a deletion will give a value of 0.5 and 2.0 depending on
whether the deleted locus is the numerator or the denominator. To
exclude the presence of polymorphisms at the primer sites, all
deletions were confirmed using at least one other set of primers to
eliminate false positive results due to mis-priming. Primer sequences
are available from the authors.
Identification of breakpoints
To identify deletion breakpoints, pairs of primers were designed for
quantitative PCR-amplification of intronic regions around the
deleted exon; these primer sequences are available from the authors.
These amplicons were multiplexed with internal controls and
analyzed for dosage. The results indicated whether each amplicon
was within the deleted region or not. Pairs of primers were
redesigned at increasing or decreasing distance from the deletion,
depending on these results, partially localizing the deletion. Where
possible, the forward primer from a diallelic region 50 of the deletion
was used with the antisense primer from a diallelic region 30 of the
deletion to amplify a PCR product straddling the deletion. This
amplicon was sequenced and the breakpoints were identified.
Amplification across breakpoints was carried out using Elongase
enzyme mix (Invitrogen, Paisley, UK) according to the manufac-
turer’s instructions, using a final concentration of 1.8 mM magnesium
with an elongation time between 5 and 20 minutes.
Haplotype analysis
Genotyping with two microsatellite markers flanking the FECH gene
(315.0 kb 50 to the start codon, 267.6 kb 30 to the stop codon) and
with one microsatellite marker in intron 4 was carried out as
described by Parker (2006).
Sequencing of genomic DNA
PCR-amplified double-stranded DNA was purified from agarose gels
using the QIAquick gel extraction kit (Qiagen) before being cycle
sequenced using fluorescent ddNTPs (BigDye) and an ABI Prism
3100 Genetic Analyzer (PE Biosystems, Warrington, UK). Nucleo-
tides are numbered from the cDNA sequence of human FECH
(GenBank accession number D00726) with the A of the ATG
initiation codon as ‘‘þ 1’’.
Other methods
Erythrocyte porphyrins were analyzed as described (Deacon and
Elder, 2001).
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